Nightstar Therapeutics Reports 2017 Financial Results and Business Highlights

Genetics Investing

Nightstar Therapeutics (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today reported financial results for the year ended December 31, 2017 and provided an update on recent corporate and clinical highlights. As quoted in the press release: “2017 was an exceptional year for the company,” said Dave Fellows, Chief Executive …

As quoted in the press release:

“2017 was an exceptional year for the company,” said Dave Fellows, Chief Executive Officer. “We set the stage for the recent initiation of the first-ever Phase 3 trial in choroideremia and today announced further data supporting the durability of the treatment effect for NSR-REP1 in choroideremia. Elsewhere in our pipeline, we initiated our Phase 1/2 gene therapy trial for X-linked retinitis pigmentosa and in-licensed our program for Stargardt disease. We also raised more than $130 million of gross proceeds from our successful Series C financing and IPO to continue our pioneering research and development activities.”

Click here to read the full press release.

disease financial results financing gene therapy ipo nsr phase 3 trial pipeline therapeutics Genetics Investing